{"id":"abrocitinib-100-mg","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Live vaccines","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Bacillus Calmette-Guérin (BCG) vaccine","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Other vaccines","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Live or attenuated vaccines","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live or attenuated)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, or inactivated)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, or inactivated, or toxoid)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, or toxoid)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, or subunit)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, or conjugate)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, or polysaccharide)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, or recombinant)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, or mRNA)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, or viral vector)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, or protein)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, or subunit)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, or conjugate)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, or polysaccharide)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, or recombinant)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, or mRNA)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, or viral vector)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, or protein)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, or subunit)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, or conjugate)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, or polysaccharide)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, or recombinant)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, or mRNA)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, or viral vector)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, or protein)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, or subunit)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, or conjugate)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, or polysaccharide)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, or recombinant)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, or mRNA)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, or viral vector)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, or protein)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, or subunit)","action":"Avoid","effect":"Decreased vaccine efficacy"},{"drug":"Vaccines (live, attenuated, inactivated, toxoid, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, conjugate, polysaccharide, recombinant, mRNA, viral vector, protein, subunit, or conjugate)","action":"Avoid","effect":"Decreased vaccine efficacy"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"9.1%","placeboRate":"","totalAtRisk":99,"totalAffected":9,"trialsReporting":1},{"effect":"Gastrooesophageal reflux disease","drugRate":"4.0%","placeboRate":"","totalAtRisk":99,"totalAffected":4,"trialsReporting":1},{"effect":"Pruritus","drugRate":"4.0%","placeboRate":"","totalAtRisk":99,"totalAffected":4,"trialsReporting":1},{"effect":"Vomiting","drugRate":"3.0%","placeboRate":"","totalAtRisk":99,"totalAffected":3,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"1.0%","placeboRate":"","totalAtRisk":99,"totalAffected":1,"trialsReporting":1},{"effect":"Alanine aminotransferase increased","drugRate":"1.0%","placeboRate":"","totalAtRisk":99,"totalAffected":1,"trialsReporting":1},{"effect":"Cough","drugRate":"1.0%","placeboRate":"","totalAtRisk":99,"totalAffected":1,"trialsReporting":1},{"effect":"Dermatitis atopic","drugRate":"1.0%","placeboRate":"","totalAtRisk":99,"totalAffected":1,"trialsReporting":1},{"effect":"Gastritis","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Asthma","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Rosacea","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Hypotension","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Dizziness","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Headache","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Eczema herpeticum","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Herpes zoster","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Joint tuberculosis","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Pharyngitis","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Pyoderma","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Varicella","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Varicella zoster virus infection","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Viral infection","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1},{"effect":"Nasopharyngitis","drugRate":"0.0%","placeboRate":"","totalAtRisk":99,"totalAffected":0,"trialsReporting":1}],"contraindications":["Antiplatelet therapies except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment.","Avoid use of CIBINQO in patients with an active, serious infection including localized infections.","Avoid use of CIBINQO in patients with severe renal impairment or end-stage renal disease.","Avoid use of CIBINQO in patients with severe hepatic impairment.","Avoid use of live vaccines prior to, during, and immediately after CIBINQO treatment."],"specialPopulations":{"Pregnancy":"Pregnancy Exposure Registry  8.1 Pregnancy \nPregnancy Exposure Registry  8.4 Pediatric Use The safety and effectiveness of CIBINQO in pediatric patients 12 years of age and older weighing 25 kg or   ...    between the pediatric patients and adults [see Clinical Studies (14) and Adverse Reactions (6.1)].  The safety and effectiveness of CIBINQO have not been established in pediatric patients below 12 years of age.   ...    In patients with severe (eGFR <30 mL/min) and moderate (eGFR 30-59 mL/min) renal impairment, the   ...    was not evaluated in patients with atopic dermatitis with baseline creatinine clearance values less than  40 mL/min. 8.7 Hepatic Impairment \nAvoid use of CIBINQO in patients with severe (Child Pugh C) hepatic impairment. Dosage adjustment is not required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic   ...    Subjects with mild hepatic impairment (Child Pugh A) had approximately 4% decrease in the combined  exposure (AUCinf,u)   ...    subjects with normal hepatic function. These changes are not clinically significant. In clinical studies,  CIBINQO has not been studied in subjects with severe (Child Pugh C) hepatic impairment, or in subjects   ...    Interactions (7.1)] \n\n8.1 Pregnancy \n8.2 Lactation \n8.3 Females and Males of Reproductive Potential \n8.4 Pediatric Use \n8.5 Geriatric Use 8.6 Renal Impairment \n8.7 Hepatic Impairment \n8.8 CYP2C19 Poor Metabolizers \n10 OVERDOSAGE \n11 DESCRIPTION   ...    Hepatic Impairment  CIBINQO is not recommended for use in patients with severe hepatic impairment [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. \n2.4 Recommended Dosage in CYP2C19 Poor Metabolizers   ...    treatment are contraindicated with CIBINQO [see Contraindications (4)]. \n13 \nReference ID: 5123487 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda \n\n8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy \nPregnancy Exposure Registry  8.4 Pediatric Use The safety and effectiveness of CIBINQO in pediatric patients 12 years of age and older weighing 25 kg or   ...    between the pediatric patients and adults [see Clinical Studies (14) and Adverse Reactions (6.1)].  The safety and effectiveness of CIBINQO have not been established in pediatric patients below 12 years of age.   ...    In patients with severe (eGFR <30 mL/min) and moderate (eGFR 30-59 mL/min) renal impairment, the   ...    was not evaluated in patients with atopic dermatitis with baseline creatinine clearance values less than  40 mL/min. 8.7 Hepatic Impairment \nAvoid use of CIBINQO in patients with severe (Child Pugh C) hepatic impairment. Dosage adjustment is not required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic   ...    Subjects with mild hepatic impairment (Child Pugh A) had approximately 4% decrease in the combined  exposure (AUCinf,u)   ...    subjects with normal hepatic function. These changes are not clinically significant. In clinical studies,  CIBINQO has not been studied in subjects with severe (Child Pugh C) hepatic impairment, or in subjects   ...    Interactions (7.1)] \n\n8.1 Pregnancy \n8.2 Lactation \n8.3 Females and Males of Reproductive Potential \n8.4 Pediatric Use \n8.5 Geriatric Use 8.6 Renal Impairment \n8.7 Hepatic Impairment \n8.8 CYP2C19 Poor Metabolizers \n10 OVERDOSAGE \n11 DESCRIPTION   ...    Hepatic Impairment  CIBINQO is not recommended for use in patients with severe hepatic impairment [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. \n2.4 Recommended Dosage in CYP2C19 Poor Metabolizers   ...    treatment are contraindicated with CIBINQO [see Contraindications (4)]. \n13 \nReference ID: 5123487 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda","Geriatric use":"8.5 Geriatric Use","Paediatric use":"The safety and effectiveness of CIBINQO in pediatric patients 12 years of age and older weighing 25 kg or   ...    between the pediatric patients and adults [see Clinical Studies (14) and Adverse Reactions (6.1)].  The safety and effectiveness of CIBINQO have not been established in pediatric patients below 12 years of age.   ...    In patients with severe (eGFR <30 mL/min) and moderate (eGFR 30-59 mL/min) renal impairment, the   ...    was not evaluated in patients with atopic dermatitis with baseline creatinine clearance values less than  40 mL/min. 8.7 Hepatic Impairment \nAvoid use of CIBINQO in patients with severe (Child Pugh C) hepatic impairment. Dosage adjustment is not required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic   ...    Subjects with mild hepatic impairment (Child Pugh A) had approximately 4% decrease in the combined  exposure (AUCinf,u)   ...    subjects with normal hepatic function. These changes are not clinically significant. In clinical studies,  CIBINQO has not been studied in subjects with severe (Child Pugh C) hepatic impairment, or in subjects   ...    Interactions (7.1)] \n\n8.1 Pregnancy \n8.2 Lactation \n8.3 Females and Males of Reproductive Potential \n8.4 Pediatric Use \n8.5 Geriatric Use 8.6 Renal Impairment \n8.7 Hepatic Impairment \n8.8 CYP2C19 Poor Metabolizers \n10 OVERDOSAGE \n11 DESCRIPTION   ...    Hepatic Impairment  CIBINQO is not recommended for use in patients with severe hepatic impairment [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. \n2.4 Recommended Dosage in CYP2C19 Poor Metabolizers   ...    treatment are contraindicated with CIBINQO [see Contraindications (4)]. \n13 \nReference ID: 5123487 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda","Renal impairment":"In patients with severe (eGFR <30 mL/min) and moderate (eGFR 30-59 mL/min) renal impairment, the   ...    was not evaluated in patients with atopic dermatitis with baseline creatinine clearance values less than  40 mL/min. 8.6 Renal Impairment: Avoid use in patients with severe renal impairment or \nend-stage renal disease. (8.6) • Hepatic Impairment: Avoid use in patients with severe hepatic impairment. \n(8.7)   ...    7.1 Effects of Other Drugs on CIBINQO \n7.2 Effects of CIBINQO on Other Drugs \n8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy \n8.2 Lactation \n8.3 Females and Males of Reproductive Potential \n8.4 Pediatric Use \n8.5 Geriatric Use 8.6 Renal Impairment \n8.7 Hepatic Impairment \n8.8 CYP2C19 Poor Metabolizers \n10 OVERDOSAGE \n11 DESCRIPTION   ...    Hepatic Impairment  CIBINQO is not recommended for use in patients with severe hepatic impairment [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. \n2.4 Recommended Dosage in CYP2C19 Poor Metabolizers   ...    treatment are contraindicated with CIBINQO [see Contraindications (4)]. \n13 \nReference ID: 5123487 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda","Hepatic impairment":"Avoid use of CIBINQO in patients with severe (Child Pugh C) hepatic impairment. Dosage adjustment is not required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic   ...    Subjects with mild hepatic impairment (Child Pugh A) had approximately 4% decrease in the combined  exposure (AUCinf,u)   ...    subjects with normal hepatic function. These changes are not clinically significant. In clinical studies,  CIBINQO has not been studied in subjects with severe (Child Pugh C) hepatic impairment, or in subjects   ...    Interactions (7.1)] \n\n8.1 Pregnancy \n8.2 Lactation \n8.3 Females and Males of Reproductive Potential \n8.4 Pediatric Use \n8.5 Geriatric Use 8.6 Renal Impairment \n8.7 Hepatic Impairment \n8.8 CYP2C19 Poor Metabolizers \n10 OVERDOSAGE \n11 DESCRIPTION   ...    Hepatic Impairment  CIBINQO is not recommended for use in patients with severe hepatic impairment [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. \n2.4 Recommended Dosage in CYP2C19 Poor Metabolizers   ...    treatment are contraindicated with CIBINQO [see Contraindications (4)]. \n13 \nReference ID: 5123487 This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=abrocitinib-100-mg","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:38:09.105544+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:38:15.246474+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:38:09.179175+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=abrocitinib-100-mg","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:38:15.758763+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Tyrosine-protein kinase JAK1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:38:17.301072+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3655081/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:38:16.968186+00:00"}},"allNames":"abrocitinib 100 mg","offLabel":[],"timeline":[],"aiSummary":"Abrocitinib 100 mg, developed by Pfizer Inc., is a marketed drug for moderate to severe atopic dermatitis. It has a mechanism of action that targets the JAK1 enzyme, which plays a key role in inflammation. The drug has shown clinical differentiation in treating patients who have had an inadequate response or intolerance to one or more biologics. Its commercial significance is evident in its high revenue of $21.2B. Abrocitinib has undergone 6 trials and has been published in 45 publications. The drug's pipeline developments are not specified. Overall, Abrocitinib is a significant addition to the treatment options for atopic dermatitis.","brandName":"Abrocitinib 100 mg","ecosystem":[],"isGeneric":true,"mechanism":{"target":"JAK1","novelty":"best-in-class","modality":"small molecule","drugClass":"Janus kinase inhibitor","explanation":"","oneSentence":"","technicalDetail":"Abrocitinib is a selective JAK1 inhibitor that blocks the activity of the JAK1 enzyme, leading to a reduction in inflammatory cytokines and alleviation of symptoms in patients with moderate to severe atopic dermatitis."},"commercial":{"revenueYear":2025,"annualCostUS":"$80,000/yr","annualRevenue":284,"genericStatus":"Generic — off-patent","revenueSource":"SEC 8-K Pfizer (2026-02-03)","currentRevenue":"$21.2B","revenueCurrency":"USD","peakSalesEstimate":"$21.2B","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T10:48:50.281182","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=abrocitinib-100-mg","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=abrocitinib-100-mg","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:32:28.593344+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Dupixent (dupilumab)","company":"Sanofi and Regeneron Pharmaceuticals","advantage":"Interleukin inhibitor, alternative treatment for atopic dermatitis, asthma, and other conditions"},{"name":"Ebglyss (lebrikizumab)","company":"Novartis","advantage":"Interleukin inhibitor, alternative treatment for atopic dermatitis"},{"name":"Triamcinolone topical","company":"Various","advantage":"Corticosteroid, alternative treatment for atopic dermatitis"},{"name":"Clobetasol topical","company":"Various","advantage":"Corticosteroid, alternative treatment for atopic dermatitis"},{"name":"Tacrolimus topical","company":"Various","advantage":"Calcineurin inhibitor, alternative treatment for atopic dermatitis"},{"name":"Dupilumab","company":"Sanofi and Regeneron Pharmaceuticals","advantage":"Interleukin inhibitor, alternative treatment for atopic dermatitis"},{"name":"Betamethasone topical","company":"Various","advantage":"Corticosteroid, alternative treatment for atopic dermatitis"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"abrocitinib-100-mg","indications":{"approved":[{"name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","regulator":"FDA"},{"name":"Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06283550","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2024-05-31","conditions":"Chronic Hand Eczema","enrollment":82},{"nctId":"NCT03422822","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-03-08","conditions":"Dermatitis, Atopic","enrollment":3166},{"nctId":"NCT06597396","phase":"PHASE2","title":"Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2024-12-27","conditions":"Post-COVID Condition, Fatigue Symptom","enrollment":46},{"nctId":"NCT05602207","phase":"PHASE4","title":"Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2022-11-25","conditions":"Atopic Dermatitis","enrollment":24},{"nctId":"NCT04564755","phase":"","title":"Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis","status":"NO_LONGER_AVAILABLE","sponsor":"Pfizer","startDate":"","conditions":"Atopic Dermatitis","enrollment":""},{"nctId":"NCT05375929","phase":"PHASE3","title":"A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-07-16","conditions":"Atopic Dermatitis","enrollment":200}],"_emaApprovals":[{"date":"","name":"Abrocitinib 100 mg","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.360iresearch.com/library/intelligence/abrocitinib-tablets","date":"2026-04-07","type":"news","title":"Abrocitinib Tablets Market Size & Share 2026-2032 - 360iResearch","source":"www.360iresearch.com"},{"url":"https://www.datainsightsmarket.com/reports/abrocitinib-tablets-302981","date":"2026-04-07","type":"news","title":"Regional Analysis of Abrocitinib Tablets Growth Trajectories","source":"www.datainsightsmarket.com"},{"url":"https://www.pharmaceutical-technology.com/features/abrocitinib-pfizer-jak-inhibitors/","date":"2026-04-07","type":"news","title":"Pfizer takes risk in pursuing more JAK inhibitor approvals","source":"www.pharmaceutical-technology.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adults","date":"2026-04-07","type":"news","title":"U.S. FDA Approves Pfizer's CIBINQO® (abrocitinib) for Adults with ...","source":"www.pfizer.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/fda-grants-priority-review-and-ema-accepts-regulatory","date":"2026-04-07","type":"news","title":"FDA Grants Priority Review and EMA Accepts Regulatory ... - Pfizer","source":"www.pfizer.com"}],"manufacturing":[],"molecularData":{"oral":true,"chemblId":"CHEMBL3655081","moleculeType":"Small molecule","molecularWeight":"323.42"},"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL3655081"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":47,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-04-01 09:48:50.313664+00","biosimilarFilings":[],"commercialAnalysis":{"text":"Abrocitinib 100 mg, developed by Pfizer, is a Janus kinase 1 (JAK1) inhibitor for the treatment of moderate to severe atopic dermatitis. As of 2025, the Abrocitinib Tablets Market size was estimated at USD 650.03 million, with a projected growth rate of 7.35% to reach USD 695.71 million in 2026 [1]. By 2032, the market is expected to reach USD 1,068.09 million [1].\n\nThe competitive landscape for Abrocitinib is relatively niche, targeting moderate to severe atopic dermatitis patients who have had an inadequate response or intolerance to one or more biologics. However, the market is not without threats, as other JAK inhibitors and biologics may compete for market share. According to Data Insights Market, the regional analysis of Abrocitinib Tablets growth trajectories indicates that the market will be driven by the increasing demand for targeted small molecules in the treatment of atopic dermatitis [2].\n\nKey upcoming catalysts for Abrocitinib include the potential for label expansions and the entry of pipeline competitors. Pfizer has seen strong results in its JAK inhibitor portfolio, with positive topline results from the fifth Phase III study of abrocitinib in moderate-to-severe atopic dermatitis patients [3]. However, the company will need to navigate patent cliffs and regulatory approvals to maintain its market position.\n\nThe market outlook for Abrocitinib is promising, with a growing demand for targeted small molecules in the treatment of atopic dermatitis. As the market continues to grow, Pfizer will need to focus on maintaining its market position and navigating the competitive landscape to ensure the long-term success of Abrocitinib.\n\nReferences:\n[1] 360iResearch, \"Abrocitinib Tablets Market Size & Share 2026-2032 - 360iResearch\" [2] Data Insights Market, \"Regional Analysis of Abrocitinib Tablets Growth Trajectories\" [3] Pharmaceutical-Technology, \"Pfizer takes risk in pursuing more JAK inhibitor approvals\"","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.360iresearch.com/library/intelligence/abrocitinib-tablets","date":"","title":"Abrocitinib Tablets Market Size & Share 2026-2032 - 360iResearch","source":"www.360iresearch.com"},{"url":"https://www.datainsightsmarket.com/reports/abrocitinib-tablets-302981","date":"","title":"Regional Analysis of Abrocitinib Tablets Growth Trajectories","source":"www.datainsightsmarket.com"},{"url":"https://www.pharmaceutical-technology.com/features/abrocitinib-pfizer-jak-inhibitors/","date":"","title":"Pfizer takes risk in pursuing more JAK inhibitor approvals","source":"www.pharmaceutical-technology.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[{"date":"2026 Feb 23","pmid":"41729754","title":"Efficacy of Abrocitinib and Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Using Treat-to-Target Goals Recommended by Experts in China.","journal":"International archives of allergy and immunology"},{"date":"2026 Feb 7","pmid":"41652607","title":"Risk assessment of asthma and allergic rhinitis in atopic dermatitis patients treated with biologics and JAK inhibitors: a systematic review and network meta-analysis of randomized controlled trials.","journal":"BMC medicine"},{"date":"2026 Dec","pmid":"41503869","title":"Dose-dependent effectiveness and patient-reported outcomes with JAK1 inhibitors in atopic dermatitis: a 36-week multicenter real-world cohort.","journal":"The Journal of dermatological treatment"},{"date":"2025","pmid":"41450456","title":"Rapid Improvement of Refractory Cutaneous Hypereosinophilic Syndrome with Abrocitinib Plus Methylprednisolone: A Case Report.","journal":"Clinical, cosmetic and investigational dermatology"},{"date":"2025 Dec 16","pmid":"41403263","title":"Efficacy and Safety of Abrocitinib in an Elderly Chinese Population with Moderate-to-Severe Atopic Dermatitis: A Non-randomized Controlled Trial.","journal":"Acta dermato-venereologica"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":4,"withResults":1},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T08:32:28.593344+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}